Drug Formulary Review Archives – January 1, 2007
January 1, 2007
View Issues
-
Analyzing reasons for ICU adverse drug events: Look beyond cost and frequency of use
The frequency, severity, and preventability of adverse drug events (ADEs) in intensive care units (ICUs) are not associated with a drug's cost or frequency of use, according to researchers writing in the American Journal of Health System Pharmacy. -
Appropriate antibiotics needed for VAP management
Clinicians who manage ventilator-associated pneumonia (VAP) patients should promote appropriate use of antibiotics to optimize patients' outcomes and prevent antibiotic resistance. -
Pharmacist-managed clinics succeed
Pharmacist-managed diabetes care clinics achieve high screening rates and attain treatment goals more often than national averages, according to two separate studies published in the American Journal of Health-System Pharmacy. -
News Brief: Special considerations for bariatric surgery patients
Patients who have undergone bariatric surgery should take steps to be sure they are absorbing their medications and nutrients, according to University of Kentucky researchers writing in the Oct. 1, 2006, American Journal of Health-System Pharmacy. -
Drug Criteria & Outcomes: Oxymorphone (Opana®) Formulary Evaluation
Oxymorphone hydrochloride (Opana® and Opana ER®) is a semi-synthetic opioid analgesic tablet for oral administration. It is a morphine-like agonist and a CII drug with an abuse liability similar to other opioids. Oxymorphone is available as 5 mg and 10 mg tablets for oral administration. -
Drug Criteria & Outcomes: New FDA Approvals
FDA recently approved these drugs: QLT USA's metronidiazole vaginal gel, 0.75%, the first generic version of 3M's MetroGel-Vaginal was approved for treating bacterial vaginosis.